564-25-0

• 常用中文名：强力霉素
• 常用英文名：Doxycycline
• CAS号：564-25-0
• 分子式：C₂₂H₂₄N₂O₈
• 分子量：444.435
• 相关类别： 原料药 抗生素类药物 四环素类药
• 发布时间：2018-05-13 08:00:00
• 更新时间：2026-07-23 04:46:49
• Doxycycline 是一种四环素抗生素,口服有效的,广谱的金属蛋白酶 (MMP) 抑制剂,具有抗菌活性。

名称

• 中文名: 强力霉素
• 英文名: doxycycline
• 中文别名: 多西环素(强力霉素)检测标准品; 强力霉素/脱氧土霉素/多西环素/6-甲基-4-(二甲氨基)-3,5,10,12,12A-五羟基-1,11-二氧代-1,4,4A,5,5A,6,11,12A-八氢-2-并四苯甲酰胺; 甲醇中强力霉素溶液标准物质; 多西环素(强力霉素)检测标准; 乙醇中强力霉素溶液标准物质; 脱氧土霉素; 犬多西环素前体; 强力霉素一水合物; 强力霉素(多西环素)标准品; 6-甲基-4-(二甲氨基)-3,5,10,12,12a-五羟基-1,11-二氧代-1,4,4a,5,5a,6,11,12a-八氢-2-并四苯甲酰胺; DOXYCYCLINE 强力霉素; 抗检测强力V2 保健酒专用强力V2 强力V1抗检测强力V2 保健酒专用强力V2 强力V1抗检测强力V2 保健酒专用强力V2 强力V1抗检测强力V2 保健酒专用强力V2 强力V1抗检测强力V2 保健酒专用强力V2 强力V1 抗检测强力V2; 2H3]-多西环素三氟乙酸盐; 多西环素; Β-多西环素; 抗检测强力V2 保健酒专用强力V2 强力V1抗检测强力V2 保健酒专用强力V2 强力V1抗检测强力V2 保健酒专用强力V2 强力V1抗检测强力V2 保健酒专用强力V2 强力V1抗检测强力V2 保健酒专用强力V2 强力V1 抗检测强力V2 保健酒专用强力V2 强力V1抗检测强力V2 保健酒专用强力V2 强; 强力霉素无水物; 强力霉素(盐酸多西环素); 抗 HIV 病毒中间体; 强力霉素(多西环素); 乙腈中强力霉素-D3; 盐酸强力霉素系列/强力霉素无水物; 强力霉素标准品; 盐酸脱氧土霉素; 甲醇中多西环素; 强力霉素 标准品 Doxycycline; Doxycycline (Synonyms: 多西环素)
• 英文别名: Monodox; azudoxat; Doxycen; 2-naphthacenecboxamide,4-alpha-s-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,1; doxiciclina; Doxycycline Base & Hyclate; doxocycline; doryx; 2-Naphthacenecboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4,5S,5,6R,12aS); doxitard; Doxycyclin hyclate; 2-Naphthacenecboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo- (6CI, 8CI); 5-hydroxy-alpha-6-deoxytetracycline; Oxytetracycline, 6-deoxy; (2E,4S,5S,5,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione hydrate; doxy-tabs; doxy-caps; investin; Ronaxan; 5-Hydroxy-6-deoxytetracycline; 5-hydroxy-alpha-6-deoxytetracyclinemonohydrate; liviatin; Unidox; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[Amino(hydroxy)methylene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2H,4H,5H)-trione; spanor; Doxivetin; Doxycycline Hydrochloride Hemiethanolat; 10,12,12a-pentahydroxy-6-methyl,1,11-dioxo-,(45-(4alpha,4aalpha,5alpha,5aalpha; 6-deoxy-oxytetracyclin; vibramycin; (4S,4,5S,5,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-cboxamide; Doxycycline (base and/or unspecified salts); MFCD02682958; Doxycycline,Doxitd,Gibidox,Liomycin; 6alpha,12aalpha)); alpha-doxycycline; 4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-(dimethylamino)-4; doxy-puren; doxitd; 2-Naphthacenecboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4α,4aα,5α,5aα,6α,12aα)]; alpha-6-deoxyoxytetracycline; methyl-1,11-dioxo-2-naphthacenecboxamidemonohydrate; DOXCYCLINEANHYDROUS; vibravenos; EINECS 209-271-1; (4S,4,5S,5,6R,12aS)- 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro -3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecboxamide Hyclate; 6-alpha-deoxy-5-oxytetracycline; DOXYCYCLINE,ANHYDROUS; 1,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dio; 6-deoxy-5-hydroxytetracycline; alpha-6-tetracyclinemonohydrate; alpha-6-deoxyoxytetracyclinemonohydrate; doxytetracycline; gs-3065; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2H,4H,5H)-trione; (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[Amino(hydroxy)methylene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5a,6,12a-tetrahydro-1,3,12(2H,4H,5H)-tetracenetrione; (4S,4,5S,5,6R,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecboxamide; DOXYCYCLINE, ANHYDROUS; Tolexine; 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecboxamide; 6- Deoxy-5-hydroxytetracycline, 6-Deoxyoxytetracycline, Doxytetracycline, GS 3065, HydraMycin, MedeoMycin, VibraMycin; DoxycyclineBp93; 6-Deoxyoxytetracycline; Deoxymykoin; Doxinyl; 6-deoxytetracycline

物化性质

• 密度: 1.6±0.1 g/cm3
• 沸点: 685.2±55.0 °C at 760 mmHg
• 熔点: 206-209ºC
• 分子式: C₂₂H₂₄N₂O₈
• 分子量: 444.435
• 闪点: 368.2±31.5 °C
• 精确质量: 444.153259
• PSA: 181.62000
• LogP: 1.36
• 外观性状: 黄色晶体粉末
• 蒸汽压: 0.0±2.2 mmHg at 25°C
• 折射率: 1.737
• 储存条件: 2-8C

生物活性

• 描述: Doxycycline 是一种四环素抗生素,口服有效的,广谱的金属蛋白酶 (MMP) 抑制剂,具有抗菌活性。
• 相关类别:
  研究领域 >> 感染
  信号通路 >> 代谢酶/蛋白酶 >> MMP
• 体外研究: 多西环素仅在高浓度下影响胶质瘤细胞的生长[2]。多西环素降低SVG细胞中MT-CO1蛋白含量,浓度为1μg/mL或更高[2]。细胞增殖测定[2]细胞系：LNT-229、G55和U343胶质瘤细胞浓度：0.01、0.1、1或10μg/mL培养时间：4天结果：仅在高浓度下影响胶质瘤细胞的生长。Western Blot分析[2]细胞系：SVG细胞浓度：0.01,0.1,1或10μg/mL培养时间：24小时结果：浓度为1μg/mL或更高的MT-CO1蛋白含量降低。
• 体内研究: 多西环素(口服；200或800mg/kg/天；3个月)以剂量依赖性方式降低未治疗HT小鼠中的活性MMP-9[1]。动物模型：6个月大的雌性杂合子Col3a1缺陷(HT)小鼠[1]剂量：200或800 mg/kg给药：口服；每天；持续3个月结果：活性MMP-9以剂量依赖性方式降低。
• 参考文献:

  [1]. Briest W, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7.

  [2]. Luger AL, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5).

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : QI8650000 CHEMICAL NAME : 2-Naphthacenecarboxamide, 4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,1 1,12a- octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-al pha-methyl-1,11-dioxo- CAS REGISTRY NUMBER : 564-25-0 LAST UPDATED : 199609 DATA ITEMS CITED : 15 MOLECULAR FORMULA : C22-H24-N2-O8 MOLECULAR WEIGHT : 444.48 WISWESSER LINE NOTATION : L E6 C666 BV FV CU GUTTT&J DQ GVZ HQ IN1&1 KQ MQ M1 RQ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 68 mg/kg/24D-I TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >2 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 378 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 228 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1870 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 410 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 241 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >100 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 750 mg/kg SEX/DURATION : female 2 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) MUTATION DATA TYPE OF TEST : DNA inhibition TEST SYSTEM : Human Lymphocyte DOSE/DURATION : 3750 ug/L REFERENCE : BCPHBM British Journal of Clinical Pharmacology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.1- 1974- Volume(issue)/page/year: 16,127,1983 *** REVIEWS *** TOXICOLOGY REVIEW PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,305,1979 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84744 No. of Facilities: 641 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 1281 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84744 No. of Facilities: 450 (estimated) No. of Industries: 1 No. of Occupations: 5 No. of Employees: 22055 (estimated) No. of Female Employees: 18813 (estimated)

安全

• 海关编码: 3004909090

合成路线

3963-95-9 ~98% 564-25-0 3219-99-6

文献：Tetrahedron Letters, , vol. 34, # 9 p. 1471 - 1474

10592-13-9 ~% 564-25-0

文献：CrystEngComm, , vol. 14, # 7 p. 2532 - 2540

上下游产品

上游产品  2
3963-95-9 10592-13-9
下游产品  2
6543-77-7 10592-13-9

海关

海关编码	3004909090